This study reports the development and characterization of rNGFSP, a novel recombinant fusion protein engineered as an immunogen to elicit therapeutic antibodies against NGF and SP, two neuropeptides that act synergistically to promote inflammation and pain associated with degenerative joint disease [[36], [37], [38]]. The gene discussed is TFF2; the disease is osteoarthritis.